Responses
Clinical and epidemiological research
Extended report
Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial
Compose a Response to This Article
Other responses
No responses have been published for this article.